Hinova Pharmaceuticals, Inc. Class ASSE: 688302

Announcement on Voluntary Disclosure of Completing First Subject Enrollment for Clinical Trial of HP515 Tablets in China

· Issued by Hinova Pharmaceuticals, Inc. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Completing First Subject Enrollment for Clinical Trial of HP515 Tablets in China

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment